The JASMINE trial (NCT06455449) is a double-blind, placebo-controlled, phase 3 study evaluating subcutaneous anifrolumab plus standard therapy in adults with dermatomyositis or polymyositis.
The rationale and design of the study are described in ACR Open Rheumatology
doi.org/10.1002/acr2...
The JASMINE trial (NCT06455449) is a double-blind, placebo-controlled, phase 3 study evaluating subcutaneous anifrolumab plus standard therapy in adults with dermatomyositis or polymyositis. The rationale and design of the study are described in ACR Open Rheumatology doi.org/10.1002/acr2...
0 vue
Publié le 20/11/2026 21:31
6:11
The JASMINE trial (NCT06455449) is a double-blind, placebo-controlled, phase 3 study evaluating subcutaneous anifrolumab plus standard therapy in adults with dermatomyositis or polymyositis.
The rationale and design of the study are described in ACR Open Rheumatology
doi.org/10.1002/acr2...
0 commentaire
?